靶剂量开搏通、倍他乐克在扩张型心肌病合并充血性心力衰竭治疗中的疗效评价  

Clinical evaluation on the effect of target dose of captopril and metoprolol to treat congestive heart failure of dilated cardiomyopathy

作　　者：陆洁[1] 张大东[1] 肖红兵[1] 金贤[1] 

机构地区：[1]上海瑞金医院集团闵行医院,201100

出　　处：《实用诊断与治疗杂志》2007年第1期17-19,共3页Journal of Practical Diagnosis and Therapy

摘　　要：目的：评价靶剂量开搏通和倍他乐克治疗扩张型心肌病合并充血性心力衰竭的疗效和安全性。方法：选择75例扩张型心肌病合并充血性心力衰竭患者，分为三组，每组25例，分别予以靶剂量开搏通、倍他乐克、开搏通联合倍他乐克治疗，观察治疗前与治疗后6～12个月、24-36个月的疗效。结果：每组治疗后6～12个月、24-36个月较治疗前均有疗效差异。但三组间疗效差异无统计学意义（P〉0．05）。结论：开搏通、倍他乐克、开搏通联合倍他乐克能明显改善扩张型心肌病充血性心力衰竭患者的心功能，安全有效。Objective To evaluate the clinical therapeutic effect and safety of target dose of captopril and metoprolol and captopril combined with metoprolol in the treatment of congestive heart failure of dilated cardiomyopathy. Methods Seventy-five patients with congestive heart failure were divided into three groups, 25 patients per group, and treated by target dose of captopril and metoprolol and captopril combined with metoprolol respectively. The therapeutic effect, and followed up at 6 to 12 months and 24 to 36 months. Results After 6 to 12 months and 24 to 36 months each therapy was effective than before, but there was no difference between each group （P 〉0. 05）. Conclusion Target dose of captropril, metoprolol or captopril combined with metoprolol is more effective in treating congestive heart failure of dilated cardiomyopathy. The therapy strategy is efficient and safe.

关 键 词：扩张型心肌病 开搏通 倍他乐克 充血性心力衰竭 靶剂量 

分 类 号：R542.2[医药卫生—心血管疾病]